Oxford, UK-based Celleron Therapeutics has signed a licensing agreement with Roche for exclusive rights to emactuzumab, a monoclonal antibody and tumour microenvironment modulator.
UK-based Celleron Therapeutics has entered an exclusive licensing agreement with Roche for global rights to the clinical development, manufacturing and commercialisation of cancer drug, emactuzumab.